8-K: Sage Therapeutics Completes Acquisition by Supernus Pharmaceuticals, Shares to Delist

Sage Therapeutics, Inc. has successfully completed its acquisition by Supernus Pharmaceuticals, Inc. through a tender offer and subsequent merger, leading to its delisting from The Nasdaq Global Market.

Summary

• Supernus Pharmaceuticals, Inc. (Parent) and its subsidiary Saphire, Inc. (Purchaser) completed the acquisition of Sage Therapeutics, Inc. (Company) through a tender offer and subsequent merger.
• The tender offer for Sage Therapeutics' common stock expired on July 30, 2025, with 36,313,509 shares validly tendered and not withdrawn, representing approximately 58% of the total outstanding shares.
• The offer price was $8.50 per share in cash, plus one contingent value right (CVR) per share, which could yield up to an additional $3.50 per share upon satisfaction of specified milestones.
• All conditions of the tender offer were satisfied, and Purchaser accepted all validly tendered shares for payment.
• The merger was consummated on July 31, 2025, making Sage Therapeutics a wholly-owned subsidiary of Supernus Pharmaceuticals, Inc.
• Shares not purchased in the tender offer were converted into the right to receive the Offer Price at the effective time of the merger.
• All outstanding in-the-money Company Options, Company RSUs, and vested Company PSUs were converted into cash payments based on the Closing Amount plus one CVR per share.
• Company Options with an exercise price equal to or greater than $8.50 were cancelled without payment.
• Unvested Company PSUs were deemed vested per the merger agreement and converted into cash payments based on the Closing Amount plus one CVR per share.
• Sage Therapeutics notified Nasdaq of the merger completion and requested the suspension of trading and delisting of its shares from The Nasdaq Global Market, effective July 30, 2025, at 8:00 p.m. Eastern Time for trading halt, and July 31, 2025, for suspension and delisting.
• The Company intends to file Form 15 with the SEC to terminate the registration of its common stock and suspend its reporting obligations.
• The merger consideration was funded through a combination of cash on the balance sheets of Parent and the Company, including proceeds from the sale of marketable securities.

Sentiment

Score: 7

Explanation: The sentiment is positive as the merger, a significant strategic event, was successfully completed as planned, providing a defined outcome for shareholders and the acquiring entity.

Positives

• The successful completion of the tender offer and merger provides a clear exit for Sage Therapeutics shareholders at a defined price.
• The satisfaction of all tender offer conditions indicates a smooth transaction process.
• The inclusion of a Contingent Value Right (CVR) offers potential for additional upside for shareholders based on future milestones.

Negatives

• Sage Therapeutics will cease to be an independent publicly traded company, leading to the delisting of its shares and loss of public market liquidity.
• Existing shareholders will no longer participate in the future growth or decline of Sage Therapeutics as an independent entity.
• The value of the CVR is contingent and not guaranteed, introducing uncertainty for the full potential payout.

Risks

• The contingent value right (CVR) payout of up to $3.50 per share is dependent on the satisfaction of specified milestones, meaning the full $3.50 is not guaranteed.
• Shareholders who did not tender their shares by the expiration date will receive the merger consideration, but the company will no longer be publicly traded, limiting future liquidity.

Future Outlook

Sage Therapeutics will operate as a wholly-owned subsidiary of Supernus Pharmaceuticals, Inc. and will no longer be a publicly traded company. It intends to terminate its SEC registration and reporting obligations.

Industry Context

This filing details the completion of a specific corporate acquisition within the pharmaceutical/biotechnology sector, rather than providing insights into broader industry trends or competitive landscapes.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received $8.50 cash per share plus one CVR per share, effectively concluding their investment in Sage Therapeutics as a publicly traded entity.
• Employees (Executives): Key executives received enhanced severance benefits and COBRA continuation, with one executive also subject to a non-compete clause, providing financial security during the transition.
• Company (Sage Therapeutics): Transformed into a wholly-owned subsidiary of Supernus Pharmaceuticals, Inc., losing its independent public company status and ceasing SEC reporting obligations.

Next Steps

• Sage Therapeutics will file a Form 25 Notification of Removal from Listing and/or Registration with the SEC to delist and deregister its shares under Section 12(b) of the Exchange Act.
• The Company intends to file a Certification and Notice of Termination of Registration on Form 15 under the Exchange Act to terminate registration of its common stock under Section 12(g) and suspend reporting obligations under Sections 13 and 15(d).

Key Dates

Recommendation

The company has been acquired and its shares are being delisted from The Nasdaq Global Market. For existing shareholders, the primary action is to ensure they receive their cash and CVR consideration. For new investors, there will no longer be a public market to trade the shares, making a 'sell' recommendation appropriate for any remaining public holdings.

Keywords

Merger, Acquisition, Tender Offer, Delisting, Contingent Value Right, CVR, Sage Therapeutics, Supernus Pharmaceuticals, Biotechnology, Pharmaceuticals, Corporate Action